What's Happening?
A new clinical trial, ENERGISE-BD, led by the Universities of Edinburgh and Birmingham, will explore whether dietary interventions can reduce depressive symptoms in individuals with bipolar disorder. The trial, funded by Wellcome with £7.9 million, will recruit
approximately 200 participants. It aims to compare the effectiveness of a high-fat, low-carbohydrate ketogenic diet against the standard NHS healthy eating advice (EatWell Guide). Participants will follow one of these diets for 12 weeks, alongside their usual medication, and will be monitored for changes in mood and energy. This research follows a smaller study by the University of Edinburgh team that suggested a ketogenic diet might be beneficial for people with bipolar disorder. The study will also assess the ease of adherence to these diets and their potential cost implications for healthcare systems. About half of the participants will undergo brain scans to understand the connection between brain chemistry changes and mood improvement.
Why It's Important?
This trial is significant as it represents the world's first large-scale randomized controlled trial investigating nutrition as a potential new treatment for bipolar depression. Bipolar disorder often involves long-term depressive symptoms that may not respond to conventional antidepressants, severely impacting quality of life. The exploration of non-pharmacological treatments, particularly dietary interventions, is a novel and promising approach, driven in part by patient reports of symptom improvement with dietary changes. If successful, the findings could lead to new, accessible treatment options for a severe mental illness, potentially reducing reliance on pharmacological interventions and improving the overall well-being of those affected. The inclusion of individuals with lived experience in the trial's design underscores a patient-centered approach, ensuring the research addresses priorities relevant to those living with the condition.
What's Next?
The ENERGISE-BD trial will initially recruit volunteers from the central belt of Scotland, with plans to expand to the Birmingham area in early 2027. Participants will be supported by dietitians throughout the 12-week dietary intervention. Researchers will analyze clinical outcomes, including changes in depressive symptoms, and assess the practical aspects of diet adherence and cost-effectiveness. The brain scan data will provide insights into the neurological mechanisms underlying any observed improvements. The study team, which includes individuals with lived experience of bipolar depression, will continue to ensure the research remains grounded in patient priorities. The results of this trial could pave the way for further research into nutritional psychiatry and potentially integrate dietary recommendations into the standard care for bipolar disorder.
Beyond the Headlines
The ENERGISE-BD trial delves into the deeper implications of the gut-brain axis and metabolic health in mental illness. The hypothesis that a ketogenic diet, by producing ketones as a more efficient brain fuel, could alleviate depressive symptoms highlights a shift towards understanding mental health through a metabolic lens. This research could challenge traditional views of mental health treatment, moving beyond solely pharmacological approaches to incorporate lifestyle and nutritional interventions. The emphasis on co-designing the research with individuals with lived experience also sets a precedent for patient-centered research in mental health, ensuring that studies address the most pressing needs and concerns of those affected. If diet proves to be an effective treatment, it could empower individuals with bipolar disorder to take a more active role in managing their condition through accessible and sustainable lifestyle changes, potentially reducing stigma associated with mental illness.
